Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight loss drugs have 1 big issue
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or complementary to the existing interventions.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold unbranded copies of those drugs are mounting a coordinated effort to reverse this decision,
How Much Do Weight Loss Drugs Cost with and without Insurance?
Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.
Weight-loss drugs lower impulse to eat – and perhaps to exercise too
Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and drugs – and now there’s evidence that it might make exercise less rewarding, to
Most U.S. employers don’t cover weight loss drugs — and fewer plan on doing so
Less than a fifth of large employers in the U.S. include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound, a KFF survey finds.
Popular Weight Loss Drugs Now for Patients With Cancer?
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.
7 common mistakes to avoid while taking popular weight loss drugs
StudyFinds' Dr. Faith Coleman looks at the common mistakes patients make using GLP-1 agonists like Ozempic and Wegovy.
FDA to review removal of Eli Lilly weight loss drug from shortage list
The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.
1d
Copycat weight loss drugs, Amazon's pharmacies, and CVS vs. Lina Khan: Pharma news roundup
If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...
STAT
3d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
1d
on MSN
Buyer beware: Off-brand Ozempic and other weight loss drugs carry hidden risks
A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.
4d
Health plans at 1 in 5 large companies cover weight-loss drugs for employees
Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Eli Lilly
United States
GLP-1
Ozempic
Wegovy
Feedback